CN102209532B - 减少小而致密的ldl颗粒的方法 - Google Patents

减少小而致密的ldl颗粒的方法 Download PDF

Info

Publication number
CN102209532B
CN102209532B CN200980144827.7A CN200980144827A CN102209532B CN 102209532 B CN102209532 B CN 102209532B CN 200980144827 A CN200980144827 A CN 200980144827A CN 102209532 B CN102209532 B CN 102209532B
Authority
CN
China
Prior art keywords
ldl
human
compound
particle size
pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980144827.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102209532A (zh
Inventor
戴维·B·卡普夫
罗纳德·M·克劳斯
崔允贞
王雪艳
弗朗辛·M·格雷瓜尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Simbei Therapy
CymaBay Therapeutics Inc
Original Assignee
Simbei Therapy
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simbei Therapy, Metabolex Inc filed Critical Simbei Therapy
Publication of CN102209532A publication Critical patent/CN102209532A/zh
Application granted granted Critical
Publication of CN102209532B publication Critical patent/CN102209532B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200980144827.7A 2008-10-17 2009-10-14 减少小而致密的ldl颗粒的方法 Active CN102209532B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10648308P 2008-10-17 2008-10-17
US61/106,483 2008-10-17
PCT/US2009/060679 WO2010045361A1 (en) 2008-10-17 2009-10-14 Methods of reducing small, dense ldl particles

Publications (2)

Publication Number Publication Date
CN102209532A CN102209532A (zh) 2011-10-05
CN102209532B true CN102209532B (zh) 2015-07-22

Family

ID=42106878

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980144827.7A Active CN102209532B (zh) 2008-10-17 2009-10-14 减少小而致密的ldl颗粒的方法

Country Status (11)

Country Link
US (3) US20100152295A1 (cg-RX-API-DMAC7.html)
EP (1) EP2346498B1 (cg-RX-API-DMAC7.html)
JP (1) JP5694941B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110091680A (cg-RX-API-DMAC7.html)
CN (1) CN102209532B (cg-RX-API-DMAC7.html)
BR (1) BRPI0920170A2 (cg-RX-API-DMAC7.html)
CA (1) CA2740874C (cg-RX-API-DMAC7.html)
ES (1) ES2712052T3 (cg-RX-API-DMAC7.html)
MX (1) MX2011004077A (cg-RX-API-DMAC7.html)
TW (1) TWI491392B (cg-RX-API-DMAC7.html)
WO (1) WO2010045361A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
KR20190060879A (ko) 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
CA2930069A1 (en) * 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2015143178A1 (en) 2014-03-20 2015-09-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
AU2015243239B2 (en) 2014-04-11 2019-11-14 Cymabay Therapeutics, Inc. Treatment of NAFLD and NASH
RU2753607C2 (ru) * 2016-10-05 2021-08-18 Митобридж, Инк. Способы лечения острого повреждения почек
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882533A (zh) * 2003-09-19 2006-12-20 詹森药业有限公司 4－((苯氧基烷基)硫基)－苯氧基乙酸及其类似物
CN101056851A (zh) * 2004-09-15 2007-10-17 詹森药业有限公司 4－((苯氧基烷基)硫基)－苯氧基乙酸及类似物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8106124A1 (es) 1979-09-05 1981-07-16 Glaxo Group Ltd Un procedimiento para la pre-paracion de fenoxialcoxifenil- derivados.
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
WO2002014291A1 (fr) 2000-08-11 2002-02-21 Nippon Chemiphar Co.,Ltd. ACTIVATEURS DE PPAR$G(d)
JPWO2002046154A1 (ja) 2000-12-05 2004-04-08 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
CA2449247A1 (en) 2001-06-11 2002-12-19 Merck & Co., Inc. A method for treating inflammatory diseases by administering a ppar-delta agonist
GB0121436D0 (en) * 2001-09-04 2001-10-24 Pfizer Ltd Biomodulated multiparticulate formulations
US20060258683A1 (en) * 2003-04-07 2006-11-16 Liu Kevin Para-sulfonyl substituted phenyl compounds as modulators of ppars
EP1637161A4 (en) 2003-04-22 2007-06-27 Astellas Pharma Inc MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST
US7199259B2 (en) 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
JP2008500358A (ja) * 2004-05-25 2008-01-10 メタボレックス インコーポレーティッド Ｐｐａｒのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法
US7622491B2 (en) * 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2015143178A1 (en) * 2014-03-20 2015-09-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
AU2015243239B2 (en) * 2014-04-11 2019-11-14 Cymabay Therapeutics, Inc. Treatment of NAFLD and NASH

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882533A (zh) * 2003-09-19 2006-12-20 詹森药业有限公司 4－((苯氧基烷基)硫基)－苯氧基乙酸及其类似物
CN101056851A (zh) * 2004-09-15 2007-10-17 詹森药业有限公司 4－((苯氧基烷基)硫基)－苯氧基乙酸及类似物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of para-alkylthiophenoxyacetic acids as a novel series of potent and selective PPARd agonists;Rui Zhang et al.;《Bioorganic & Medicinal Chemistry Letters》;20070510;第3855-3859 *

Also Published As

Publication number Publication date
US11007162B2 (en) 2021-05-18
US20190298672A1 (en) 2019-10-03
CA2740874C (en) 2018-02-27
BRPI0920170A2 (pt) 2016-06-21
TWI491392B (zh) 2015-07-11
KR20110091680A (ko) 2011-08-12
JP2012505905A (ja) 2012-03-08
EP2346498A4 (en) 2012-08-01
ES2712052T3 (es) 2019-05-09
US20100152295A1 (en) 2010-06-17
MX2011004077A (es) 2011-08-17
TW201028141A (en) 2010-08-01
US20160324811A1 (en) 2016-11-10
CA2740874A1 (en) 2010-04-22
EP2346498A1 (en) 2011-07-27
CN102209532A (zh) 2011-10-05
JP5694941B2 (ja) 2015-04-01
EP2346498B1 (en) 2018-12-26
WO2010045361A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
US11007162B2 (en) Methods of reducing small, dense LDL particles
US20090131489A1 (en) 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US8242173B2 (en) 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US7598416B2 (en) 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
HK1159492A (en) Methods of reducing small, dense ldl particles
HK1159492B (en) Methods of reducing small, dense ldl particles
HK1101758B (en) 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
HK1104523B (en) 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MXPA06004897A (en) Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: American California

Applicant after: Ximabei Therapeutics Corporation

Address before: American California

Applicant before: Metabolex Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: METABOLEX INC. TO: XIMABEI THERAPEUTICS CORPORATION

C14 Grant of patent or utility model
GR01 Patent grant